tirzepatide glaucoma Use of the dual GIP/GLP-1 drug (Mounjaro, Zepbound) was associated with a significantly reduced risk of compared with GLP-1 drugs among patients with type 2 diabetes, a large retrospective cohort What Is Tirzepatide? How It

You should contact your GP or mental health team urgently if you experience any of the following whilst taking Mounjaro: Significant changes in mood (either elevated or depressed) Increased anxiety or agitation Changes in sleep patterns (insomnia or excessive sleeping) Thoughts of self-harm or suicide (if at immediate risk, call 999 or go to A&E) Severe or persistent gastrointestinal symptoms affecting your ability to eat or take medications Signs of dehydration Symptoms of hypoglycaemia if also taking insulin or sulfonylureas (shakiness, sweating, confusion) Additionally, seek medical advice if you notice any unusual physical symptoms such as: Severe abdominal pain Persistent vomiting Signs of pancreatitis (severe upper abdominal pain radiating to the back) Symptoms of gallbladder disease (pain in the right upper abdomen, fever, jaundice) Symptoms of thyroid problems (lump in the neck, hoarseness, difficulty swallowing) Changes in vision, particularly if you have diabetic retinopathy While rare, these require prompt medical assessment

Weeks 9+: Doses from 7.5 mg to 15 mg Weeks 9+: Gradually increase your dose by 2.5 mg every four weeks, starting at 7.5 mg (green label) and going up to a maximum of 15 mg (orange label), depending on your target dose and tolerance

Only a healthcare professional can provide the proper guidance on whether to stop or continue the medication

Time in restorative deep sleep increases

At Prestige Medical Group, our Tirzepatide is compounded with BPC-157 peptide for enhanced tolerability and wellness support addressing the GI side effects commonly associated with GLP-1 and GLP-1/GIP medications